Antibodies are versatile tools for treating cancer, immunological disorders, and central nervous system (CNS) diseases. Developing antibody therapeutics demands sophisticated tools and deep expertise. JAX offers next-generation transgenic mice for monoclonal and bispecific antibody discovery, plus a suite of humanized mouse models for the evaluation of pharmacokinetics, efficacy, and safety. Trust JAX for the best models and services to accelerate your antibody discovery programs.
Transgenic mice for monoclonal, bispecific, and multispecific antibody discovery.
Translational data from PDX, cell lines, humanized CD34+/PBMC mice, and genetically engineered models.
Test optimal dosage and cytokine response based on unique PBMC profiles.
Our specialized models generate antibodies with the optimal diversity, developability, and affinity required to accelerate your antibody discovery programs and bring life-saving therapeutics into the clinic faster.
Through our partnership with AbTherx, we offer advanced transgenic platforms for monoclonal, bispecific and multispecific antibody discovery. We've combined our decades of experience in transgenic mice with AbTherx's, our deep knowledge in antibody discovery to help you create the next generation of antibody therapeutics.
Increasingly, antibodies are being engineered to improve safety, efficacy, and clinical success. JAX provides humanized mice that support every stage of preclinical development, from PK to toxicity.
Obtain translational PK with JAX’s genetically-humanized FcRn platforms. Choose models that match your therapeutic's design and immunogenicity to refine your first-in-human dose.
Use JAX’s unrivaled NSG® mice engrafted with human PBMCs to study donor-to-donor differences and engage human-specific targets.
Select from our range of immune-humanized mouse models to ensure the right immune cell populations for your therapeutic’s mode of action. Test the safety and efficacy with or without a PDX or CDX tumor.
